 Saponin adjuvant compositions |
| What is claimed is: 1. A Quillaja saponaria saponin composition for eliciting an immune response in ... |
|
| Quercetin derivatives and their medical usages |
| The invention claimed is: 1. A purified compound of formula I ##STR00002## wherein R.sub.1, R.sub.2,... |
|
| Islet cells from human embryonic stem cells |
| This invention solves the problem of generating large populations of human islet cells by showing ... |
|
| Neural thread protein gene expression and detection of alzheimer's disease |
| A need exists for a definitive diagnostic test which can be performed on individuals suspected of ... |
|
| Method of detecting neurological disease or dysfunction |
| What is claimed is: 1. A method for detecting the presence of nPTP in a human subject, said method ... |
|
| Metabolic pathway assay |
| This invention relates to an in vitro screening assay which identifies enzyme inhibitors. This ... |
|
| MurC |
| What is claimed is: 1. An isolated polynucleotide segment comprising a first polynucleotide ... |
|
| Murf gene and enzyme of Pseudomonas aeruginosa |
| Polynucleotides and polypeptides of Pseudomonas aeruginosa MurF, an enzyme involved in bacterial ... |
|
| Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold |
| It is an object of the invention to provide a method of affecting nociception. It is an object of ... |
|
| Liposomal transfection method |
| The object of the present invention is thus a method for transfecting a cell with a nucleic acid ... |
|
|
Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
| Details |
Inventors: Goldenberg, David Milton; Griffiths, Gary L.; Hansen, Hans J.;
Assignee: Immunomedics, Inc. (Morris Plains, NJ)
Primary Examiner: Eisenschenk; Frank C.
Assistant Examiner:
Attorney, Agent or Firm: Foley & Lardner
Improved methods of detecting and/or treating lesions in a patient are provided. The improved methods comprise the steps of (a) parenterally injecting a subject with a targeting composition comprised of a conjugate of biotin and targeting protein or of an avidin and targeting protein, wherein the targeting protein preferentially binds to a marker substance produced or associated with the targeted lesion, and allowing the targeting protein conjugate to preferentially accrete at the targeted lesion; (b) then parenterally injecting a clearing composition comprised of (i) avidin, when the targeting composition is a biotin-targeting protein conjugate, or (ii) biotin, when the targeting composition is a avidin-targeting protein conjugate, and allowing the clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion; (c) parenterally injecting a localization agent which may be the same or different form the clearing agent; (d) parenterally injecting a detection or therapeutic composition comprised of a conjugate of (i) avidin and naturally occurring metal-ion chelating protein chelated with chelatable metal detection or therapeutic agent when the clearing composition is biotin, or (ii) biotin and naturally occurring metal-ion carry protein chelated with chelatable a metal detection or therapeutic agent when the clearing agent is avidin, and allowing the composition to accrete at the targeted lesion. The improvement is that the use of the chelating protein to chelate a chelatable metal therapeutic or detection agent amplifies the amount of detection or therapeutic agent at the targeted site. |
|
DETAILED DESCRIPTION We claim: 1.
In a method for targeting a diagnostic or therapeutic metal ion to a lesion in a patient, comprising the steps of: (a) administering by parenteral injection a biotinylated targeting conjugate comprising biotin and an antibody or antibody fragment that preferentially binds a marker substance produced by or associated with a lesion, thereby accreting said targeting conjugate preferentially at said lesion; (b) administering by parenteral injection a clearing and localizing agent comprised of avidin or a biotin-binding avidin derivative thereby (i) binding and preferentially localizing said agent to said targeting conjugate accreted at said lesion, and (ii) binding said agent to unaccreted targeting conjugate to clear said unaccreted conjugate from said patient; (c) administering by parenteral injection a biotinylated metal ion delivery conjugate comprising biotin, a metal ion chelating agent and metal ions chelated to said agent, thereby binding said metal ion delivery conjugate to avidin in said agent localized at said lesion and targeting said metal ion to said lesion, and (d) detecting or treating said lesion by said targeted metal ion; the improvement wherein, said metal ion chelating agent is a naturally occurring protein that chelates a plurality of metal ions and wherein said naturally occurring protein has a molecular weight of at least about 60,000 Daltons.
2.
The method of claim 1, wherein the lesion is cancerous, cardiovascular, infectious or inflammatory.
3.
The method of claim 2, wherein the cardiovascular lesion is a thrombus, embolus, infarct or atherosclerotic plaque.
4.
The method of claim 2, wherein the cancerous lesion is a carcinoma, melanoma, sarcoma, neuroblastoma, leukemia, lymphoma, glioma, myeloma or neural tumor.
5.
The method of claim 2, wherein the lesion is infectious or inflammatory.
6.
The method of claim 1, wherein the antibody or antibody fragment is a monoclonal antibody, or a specific binding fragment thereof.
7.
The method of claim 6, wherein the fragment is a Fv, single chain antibody, Fab, Fab', F(ab)
|
|
Gene Therapy 
